对于传统角膜移植无法复明的严重眼表损伤终末期角膜盲患者，合成硬质人工角膜是脱盲的最后希望。目前主要问题是人工角膜和周围组织不能完全生物整合，由此造成人工角膜严重并发症而影响其发展。本课题拟整合现有人工角膜优势，模拟骨齿型人工角膜的牙槽骨支架设计，发挥俄罗斯MICOF和美国Boston人工角膜批量生产的优势，采用脱细胞骨基质为支架材料，骨髓间充质干细胞为种子细胞，形成具有生物活性人工角膜支架。在细胞和分子水平上认识DBM复合BMSCs与宿主角膜微环境中与形成环境及其特征与体内生物活性分子和细胞的相互作用；通过动物实验验证植入该人工角膜支架的安全性和有效性；通过microRNA芯片技术，探讨生物活性支架对植入术后人工角膜周围组织微环境的影响；从基因水平、蛋白水平以及炎症通路三方面来验证microRNA作用机制，为解决人工角膜长期稳定效果的关键问题提供理论基础，为临床治疗和并发症预防提供新思路。

End-stage corneal blindness could not restore sight except for keratoprosthesis. PMMA has remained a popular material of choice in KPro because of its excellent optical properties and biocompatibility, although its biointegration in cornea tissue is known to be poor.Here, decalcified bone matrix(DBM), which has demonstrated excellent biointegration in orthpedics with the prospect that it may enhance the integration of the material with the corneal tissue. Because of the host cornea’s insufficiency and weekly proliferative capacity, autologous bone mesenchymal stem cells (BMSCs) will be combined with DBM as skirt of keratoprosthesis. ECM including the collagen, MMPs and GAGs will be investigated by western blot, immunohistochemistry, RT-PCR and flow cytometry cell staining in order to understand the surrounding tissue of the graft biological behavior and function.